Abstract 4668
Background
Long-term survival is poor for patients with locally advanced or metastatic urothelial carcinoma (UC) receiving chemotherapy and/or immunotherapy following progression with platinum-containing chemotherapy. Genetic alterations of fibroblast growth factor receptors (FGFR) have been shown to play a role in UC development and progression. Non-genetic and epigenetic activation of FGFR gene expression have also been described. Rogaratinib, an oral pan-FGFR 1-3 inhibitor, has shown promising activity and a manageable safety profile in a phase I study in patients with UC who were selected based on FGFR1-3 mRNA overexpression and/or activating mutations in the FGFR3 gene.
Trial design
This is a randomized, open-label, phase 2/3 study to evaluate the efficacy and safety of rogaratinib compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic UC who have received prior platinum-containing chemotherapy. The primary objective is to show superiority of rogaratinib over chemotherapy in prolonging overall survival (OS) of UC patients with FGFR-positive tumors. Secondary objectives include: objective response rate (ORR), progression-free survival, disease control rate, duration of response, and safety. Testing for FGFR1 and 3 mRNA over expression will be conducted centrally using an RNA in situ hybridization (RNA-ISH) in archival samples. Eligible patients will be randomized 1:1 to rogaratinib (800 mg po bid) or iv chemotherapy Q3W (docetaxel 75 mg/m2; paclitaxel 175 mg/m2; or 320 mg/m2 vinflunine). Randomization will be stratified according to PIK3CA and/or RAS activating mutations, prior immunotherapy, and modified 4-factor Bellmunt risk score. The objective for the phase 2 part of the study is ORR. A total of 116 patients in PIK3CA and RAS WT patients will be enrolled to the phase 2 part of the study to rule out a low difference in ORR between rogaratinib and chemotherapy as futility. The phase 3 portion of the study is powered to detect an increase in median OS in PIK3CA and RAS WT patients. Total patient enrollment expected to be approximately 400 patients.
Clinical trial identification
NCT03410693.
Legal entity responsible for the study
Bayer AG.
Funding
Bayer AG.
Editorial Acknowledgement
Disclosure
K. Nakajima, C. Lu, A. Holynskyj: Bayer employment. All other authors have declared no conflicts of interest.
Resources from the same session
2069 - The concordance with antiemetic guideline for pediatric, adolescent and young adult patients with cancer using a large-scale administrative database.
Presenter: Seiko Bun
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2740 - Effectiveness of surgical glove compression therapy as a prophylactic method against nab-Paclitaxel induced peripheral neuropathy
Presenter: Shigeru Tsuyuki
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2229 - Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)
Presenter: Hubert Piessevaux
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4155 - Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV)
Presenter: Antony Mersiades
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2473 - Pregnancies after breast cancer, is there a real need for fertility preservation ? Results from the ARTEMIS cohort of 60 young patients
Presenter: Jerome Martin-Babau
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3450 - Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: a reality or a myth?
Presenter: Aurore Vozy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2917 - Indicators of non-uptake of breast cancer screening: results from the EDIFICE 6 survey
Presenter: Jean-Francois Morere
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2920 - Benefits of physical activity and sport integrated into the care pathway of oncology patient
Presenter: Laurence Vanlemmens
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5334 - Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study
Presenter: Quan Tran
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
6108 - Quality of life, late effects, and related clinical factors among Korean colorectal cancer survivors
Presenter: Ji Soo Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract